University Health Network
Toronto, Ontario, Canada
Location status: Recruiting
Location contact
Desana Thayaparan, BSc
CONTACT
Douglas Lee, MD, PhD
CONTACT
NCT Number: NCT05028686
This study is a prospective registry that aims to predict readmissions in patients with heart failure, using -omics, machine learning, patient reported outcomes, clinical data and other high-dimensional data sources.
Interested in participating?
Request Info18 year–105 year
All sexes
Observational
Toronto, Ontario, Canada
Location status: Recruiting
Desana Thayaparan, BSc
CONTACT
Douglas Lee, MD, PhD
CONTACT
There is substantial need to better predict outcomes across the spectrum of heart failure (HF) phenotypes in order to provide more efficient care with greater precision. Specifically, no validated methods have been adopted to predict outcomes reflecting transitions in health status across the continuum of HF and changes in cardiac function. A key transition is hospitalization - either readmission or de novo cardiovascular hospital admission. This is a major unmet health care need, to be able to better predict who will require hospital admission.
Novel contributions of biomarkers, -omics, remote patient monitoring, and artificial intelligence (AI). It is anticipated that prediction of readmission and many other outcomes will be further improved by measurement of circulating biomarkers and by incorporating methods from AI including machine learning and probabilistic generative models that can incorporate the lens of how physicians and patients think. Machine learning that incorporates many different types of data, including physician interpretation and a broad array of biomarker/-omics molecular information can lead to significant improvements in predictive accuracy. Novel multimarker strategies coupled with machine learning may enable the ability of physicians to predict a range of outcomes (e.g., transitions in HF health status and LVEF) and refine clinical prediction models. Furthermore, the investigators will collect patient data, including patient reported outcome measures (PROMs), and physiological data (e.g. heart rate, blood pressure, and daily weights data) and integrate these data points into predictive models. The investigators will use the PROMs obtainable using Medly as a predictor of hospitalization, and as an outcome. In this proposal, the investigators will take advantage of recent advances in both deep and high throughput proteomics technologies to perform high-resolution analyses. These novel factors can be integrated into new electronic algorithms to improve HF care in the population.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Observational cohort
Time frame: 30 day
Non-elective readmission to hospital for a cardiovascular cause
Time frame: 30 day
Non-elective readmission to hospital for heart failure
Time frame: 30-day
All-cause death
Time frame: 30-day
Death from cardiovascular causes
Time frame: 30-day
Non-elective readmission to hospital for a any reason
Contact information is provided by the study sponsor or research team.
Douglas S Lee, MD, PhD
CONTACT
Suzanne Perrett
CONTACT
Institute for Clinical Evaluative Sciences
Other
Acronym: PROBE AI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07081711
Aortic Diseases, Arrhythmias, Cardiac
Cleveland, Ohio, United States
View Trial DetailsNCT07592494
Cardiac Resynchronization Therapy Devices, Cardiovascular Diseases
Çorum, Turkey (Türkiye)
View Trial DetailsNCT07574593
Cardiovascular Diseases, Heart Diseases
Chula Vista, California, United States
View Trial DetailsNCT07278583
Cardiovascular Diseases, Heart Diseases
Clermont-Ferrand, France
View Trial Details